Common Side Effects
Hematologic Toxicity
Neutropenia may occur; regular complete blood count monitoring is required. Dose adjustment or treatment interruption may be necessary in severe cases.
Gastrointestinal Reactions
Diarrhea (mostly grade 1–2), nausea, and vomiting, which can be managed with symptomatic medications.
Fatigue and Liver Enzyme Elevation
Some patients experience elevated transaminases; liver function should be monitored.
Other Reactions
Headache, alopecia, etc., which are generally mild.
Precautions for Use
Dose Adjustment
Dose should be adjusted based on the severity of side effects. The usual starting dose is 150 mg twice daily, taken with food.
Contraindications
Contraindicated during pregnancy due to embryotoxicity. Use with caution in patients with severe hepatic or renal impairment.
Drug Interactions
Avoid concomitant use with strong CYP3A4 inhibitors or inducers, which may alter plasma drug concentrations.
Monitoring Parameters
During treatment, regular monitoring of complete blood count, liver and renal function, and electrocardiography is recommended (QT interval prolongation may occur in a small number of patients).
Research Progress
Abemaciclib has demonstrated potential efficacy against other solid tumors (such as non‑small cell lung cancer and glioblastoma) in clinical trials, but its current approved indications remain focused on breast cancer.Researchers are also exploring combination regimens with immunotherapies and other targeted agents to further expand its clinical applications.
